Search
fluoxymesterone (Haloestin, Ora-Testryl)
Tradenames: Haloestin, Ora-Testryl. DEA controlled substance. Class 3.
Indications:
- males:
- androgen deficiency
- replacement therapy in hypogonadism & delayed puberty
- orchitis
- scrotal pain/mass
- cryptorchidism
- Klinfelter's syndrome
- anorchia [4]
- females:
- metastatic breast cancer
- post-partum breast engorgement
- both
- LHRH deficiency
- anemia
- myotonia congenita [4]
Dose:
1) hypogonadism 5-20 mg PO QD
2) inoperable breast cancer
a) 10-20 mg/day in divided doses
b) continue for 1 month for a subjective response
c) continue for 2-3 months for an objective response
Tabs: 2, 5, 10 mg.
Adverse effects:
1) common (> 10%)
- edema, acne, breast soreness
2) less common (1-10%)
- GI irritation, nausea/vomiting, hepatic dysfunction, 3 uncommon (< 1%)
- hepatic necrosis, leukopenia, hypercalcemia, polycythemia, cholestatic hepatitis, hypersensitivity
4) males
- gynecomastia
- priapism
- male pattern baldness
- retention of water & electrolytes
- suppression of clotting factors
- prostatic hypertrophy & prostate carcinoma
- impotence
- testicular atrophy
5) females
- amenorrhea
- deepining of the voice
- clitoral enlargement
- hirsutism
Drug interactions:
1) fluoxymesterone increases anti-coagulant effect of warfarin
2) cyclosporine
Mechanism of action: androgen
Interactions
drug adverse effects of androgens
General
androgen or anabolic steroid
Properties
MISC-INFO: elimination route LIVER
pregnancy-category X
safety in lactation ?
Database Correlations
PUBCHEM correlations
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Drug Information & Medication Formulary, Veterans Affairs,
Central California Health Care System, 1st ed., Ravnan et al
eds, 1998
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Deprecated Reference